Physician profile
Benjamin Scott Robey
NPI 1043607203
$6,574.96
in general payments reported to CMS, 2019-2025
34 companies · $3,244 in 2025
The $3,244 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.60 · 2023: $1,004 · 2024: $2,288 · 2025: $3,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239 · Consulting Fee: $1,200 · Education: $96.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.63 |
| Consulting Fee | $1,200.00 |
| Education | $96.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.19 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Genzyme Corporation | $1,356.12 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $417.83 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Biotronik Nro, INC. | $384.87 | 2024-2025 | Prospera |
| Lilly USA, LLC | $362.05 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Pfizer INC. | $312.73 | 2022-2025 | |
| Qol Medical, LLC | $267.05 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $259.01 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $219.25 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $204.19 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $148.70 | 2023-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $143.44 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Celltrion USA INC. | $100.01 | 2024-2025 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $90.91 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.80 | 2023-2024 | Cyltezo, Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $68.41 | 2024-2025 | Voquezna |
| Abbott Laboratories | $66.81 | 2024 | Freestyle Libre 3, Proclaim |
| Daiichi Sankyo INC. | $57.57 | 2023-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $57.07 | 2025 | |
| Gilead Sciences, INC. | $49.45 | 2025 | |
| Sanofi-Aventis U.S. LLC | $33.02 | 2024 | |
| Mirum Pharmaceuticals, INC. | $23.98 | 2024 | Livmarli |
| Madrigal Pharmaceuticals | $23.82 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2024 | |
| Grifols USA, LLC | $19.62 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $17.14 | 2024 | Dificid |
| Capsovision, INC. | $16.02 | 2023 | Capsocam Plus |
| Vivus LLC | $15.89 | 2024 | Qsymia |
| Phadia US INC. | $15.44 | 2024 | Immunocap |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
| Fresenius Kabi USA, LLC | $14.74 | 2023 | Idacio |
| Amgen INC. | $14.21 | 2023 | Evenity, Prolia |
| Celgene Corporation | $13.76 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Robey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.